ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - ofatumumab 20 mg/ml - concentrate for solution for infusion - ofatumumab - treatment of chronic lymphocytic leukaemia (cll) in patients who are refractory to fludarabine and alemtuzumab

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - ofatumumab 20 mg/ml - concentrate for solution for infusion - ofatumumab - treatment of chronic lymphocytic leukaemia (cll) in patients who are refractory to fludarabine and alemtuzumab

ישראל - עברית - Ministry of Health

novartis israel ltd - ofatumumab - תמיסה להזרקה - ofatumumab 50 mg/ml - ofatumumab

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - rituximab - תרכיז להכנת תמיסה לאינפוזיה - rituximab 10 mg/ml - rituximab - rituximab - mabthera is indicated for the following indications: * non-hodgkin’s lymphoma (nhl)mabthera is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, b-cell non-hodgkin’s lymphoma.mabthera is indicated for the treatment of previously untreated patients with low-grade or follicular lymphoma in combination with chemotherapy mabthera is indicated for the treatment of patients with cd20 positive diffuse large b-cell non-hodgkin's lymphoma in combination with chop chemotherapy. mabthera maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy. * chronic lymphocytic leukaemia (cll)mabthera in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including mabthera or patients refractory to previous mabthera plu

ישראל - עברית - Ministry of Health

padagis israel agencies ltd, israel - rituximab - תרכיז להכנת תמיסה לאינפוזיה - rituximab 10 mg/ml - rituximab

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - rituximab - תמיסה להזרקה - rituximab 1400 mg / 11.7 ml - rituximab

ישראל - עברית - Ministry of Health

novartis israel ltd - rituximab - תרכיז להכנת תמיסה לאינפוזיה - rituximab 10 mg / 1 ml - rituximab

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - obinutuzumab - תרכיז להכנת תמיסה לאינפוזיה - obinutuzumab 1000 mg / 40 ml - obinutuzumab

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - trastuzumab - תמיסה לאינפוזיה - trastuzumab 440 mg/ml - trastuzumab - trastuzumab - herceptin is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2: 1. as a single agent for the treatment of those patients who have received one or more chemotherapy regiments for their metastatic disease. 2. in combination with paclitaxel or docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease. 3. herceptin in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive metastatic breast cancer. early breast cancer (ebc) :herceptin is indicated to treat patients with her2-positive early breast cancer following surgery and chemotherapy (neoadjuvant or adjuvant) either alone or in combination with chemotherapy excluding anthracyclines. herceptin should only be used in patients whose tumors have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay.her2 metastatic gastric cancer (mgc)herceptin in

ישראל - עברית - Ministry of Health

j-c health care ltd - daratumumab - תרכיז להכנת תמיסה לאינפוזיה - daratumumab 20 mg / 1 ml - daratumumab